Uptravi selexipag regulatory update

EMA’s CHMP recommended Uptravi selexipag from Actelion to treat pulmonary arterial hypertension (PAH). Specifically, CHMP recommended Uptravi for the long-term treatment of PAH in adult patients with WHO functional class II-III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist and/or a phosphodiesterase-5 (PDE-5) inhibitor or as monotherapy in patients who are not candidates for these therapies. ...